3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
14
Brain Neoplasms
12
Lung Neoplasms
8
Neoplasm Metastasis
7
Pancreatic Neoplasms
6
Liver Neoplasms
6
Glioblastoma
6
Squamous Cell Carcinoma of Head and Neck
5
Carcinoma, Hepatocellular
5
Prostatic Neoplasms
4
Melanoma
4
Carcinoma, Renal Cell
4
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Neurologic Manifestations
2
Glioma
2
Colorectal Neoplasms
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Unspecified Adult Solid Tumor
1
Stomach Neoplasms
1
Spinal Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Interventions
Ipilimumab
5
pembrolizumab
3
Nivolumab
3
Paclitaxel
2
Oxaliplatin
2
Doxorubicin
2
Capecitabine
2
CTLA-4 Antigen
2
tremelimumab
1
trastuzumab deruxtecan
1
tebentafusp
1
spartalizumab
1
lenvatinib
1
eribulin
1
envafolimab
1
durvalumab
1
Vemurafenib
1
Surgical Procedures, Operative
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Leucovorin
1
Immunotherapy
1
Fluorouracil
1
Docetaxel
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Radiosurgery
×
Clear all
NCT05915481
2023-06-23
SCARCE
Peking University Third Hospital
Phase 1/2
Unknown
60 enrolled